Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02711995 · ClinicalTrials.gov registry record · NA
Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation
A NA study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT02711995 is a NA study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 8 participants.
The verdict
NCT02711995, a NA study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Botulinum toxin is the common treatment of choice for patients with Essential Voice Tremor (EVT), but results are not universally beneficial to all patients. Inconsistent results are noted in the literature and are consistent with the PI's clinical experience. Injection augmentation, a well-established treatment for glottic insufficiency, which is a prominent factor in the clinical presentation of Essential Voice Tremor (EVT), has not been studied. By treating patients at separate times with botulinum toxin and injection augmentation in an unblinded prospective crossover treatment study, we can assess functional outcomes of these two treatments with the population of patients with Essential Voice Tremor (EVT).
Interventions
- DRUG Botulinum Toxin
- DRUG RenuGel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-12-15 |
| Est. Completion | 2016-09-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02711995
The ClinicalTrials.gov registry entry for NCT02711995 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Botulinum Toxin is the first listed.
NCT02711995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02711995 about?
NCT02711995 is a clinical study titled "Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation". Botulinum toxin is the common treatment of choice for patients with Essential Voice Tremor (EVT), but results are not universally beneficial to all patients. Inconsistent results are noted in the literature and are consistent with the PI's clinical experience. Injection augmentation, a well-establis...
What is the current status of trial NCT02711995?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2015-12-15. Estimated completion is 2016-09-29.
What interventions are being tested in trial NCT02711995?
The interventions under investigation include: Botulinum Toxin (DRUG), RenuGel (DRUG).
Who is sponsoring clinical trial NCT02711995?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.